| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EHHADH |
| Uniprot No | Q08426 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-723aa |
| 氨基酸序列 | MAEYTRLHNALALIRLRNPPVNAISTTLLRDIKEGLQKAVIDHTIKAIVICGAEGKFSAGADIRGFSAPRTFGLTLGHVVDEIQRNEKPVVAAIQGMAFGGGLELALGCHYRIAHAEAQVGLPEVTLGLLPGARGTQLLPRLTGVPAALDLITSGRRILADEALKLGILDKVVNSDPVEEAIRFAQRVSDQPLESRRLCNKPIQSLPNMDSIFSEALLKMRRQHPGCLAQEACVRAVQAAVQYPYEVGIKKEEELFLYLLQSGQARALQYAFFAERKANKWSTPSGASWKTASARPVSSVGVVGLGTMGRGIVISFARARIPVIAVDSDKNQLATANKMITSVLEKEASKMQQSGHPWSGPKPRLTSSVKELGGVDLVIEAVFEEMSLKKQVFAELSAVCKPEAFLCTNTSALDVDEIASSTDRPHLVIGTHFFSPAHVMKLLEVIPSQYSSPTTIATVMNLSKKIKKIGVVVGNCFGFVGNRMLNPYYNQAYFLLEEGSKPEEVDQVLEEFGFKMGPFRVSDLAGLDVGWKSRKGQGLTGPTLLPGTPARKRGNRRYCPIPDVLCELGRFGQKTGKGWYQYDKPLGRIHKPDPWLSKFLSRYRKTHHIEPRTISQDEILERCLYSLINEAFRILGEGIAASPEHIDVVYLHGYGWPRHKGGPMFYASTVGLPTVLEKLQKYYRQNPDIPQLEPSDYLKKLASQGNPPLKEWQSLAGSPSSKL |
| 预测分子量 | 95.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EHHADH重组蛋白的模拟参考文献示例(注：文献信息为示例性质，非真实文献)：
---
1. **文献名称**: *"Recombinant EHHADH overexpression alters peroxisomal fatty acid metabolism in vitro"*
**作者**: Smith A, et al.
**摘要**: 本研究通过构建重组EHHADH蛋白，验证其在过氧化物酶体中对长链脂肪酸β氧化的调控作用，发现其过表达可抑制酰基辅酶A代谢通量，提示EHHADH可能作为代谢平衡的关键酶。
---
2. **文献名称**: *"Structural and functional characterization of human EHHADH using recombinant expression systems"*
**作者**: Lee J, et al.
**摘要**: 利用大肠杆菌系统成功表达并纯化人源EHHADH重组蛋白，通过晶体结构解析和酶活实验，揭示了其双功能酶(水解酶/脱氢酶)活性中心的分子机制。
---
3. **文献名称**: *"EHHADH deficiency exacerbates metabolic syndrome via impaired peroxisomal lipid handling"*
**作者**: Zhang Y, et al.
**摘要**: 通过构建EHHADH基因敲除小鼠模型并结合重组蛋白回补实验，证明EHHADH缺失导致过氧化物酶体脂代谢紊乱，进而加重胰岛素抵抗和肝脏脂肪堆积。
---
4. **文献名称**: *"Role of EHHADH in renal tubular acidosis: Insights from recombinant protein interaction assays"*
**作者**: Gupta R, et al.
**摘要**: 利用重组EHHADH蛋白进行体外结合实验，发现其与肾小管细胞中特定转运蛋白的相互作用异常可能导致远端肾小管酸中毒的分子病理机制。
---
注：以上为模拟文献，实际研究中请通过PubMed、Web of Science等平台以关键词“EHHADH recombinant”“EHHADH peroxisome”等检索最新文献。
EHHADH (Enoyl-CoA Hydratase and 3-Hydroxyacyl CoA Dehydrogenase) is a bifunctional enzyme critical in fatty acid β-oxidation, a metabolic pathway that breaks down fatty acids into acetyl-CoA for energy production. This peroxisomal and mitochondrial protein catalyzes two sequential reactions: the hydration of enoyl-CoA to 3-hydroxyacyl-CoA and the subsequent dehydrogenation to 3-ketoacyl-CoA. Its dual activity supports cellular energy homeostasis, particularly in tissues with high metabolic demands, such as the liver and kidneys.
Recombinant EHHADH refers to the protein produced via genetic engineering, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cell lines). This approach enables large-scale production of purified, functional EHHADH for research and therapeutic applications. Researchers use recombinant EHHADH to study its structural features, enzymatic mechanisms, and regulatory roles in lipid metabolism. It has also been instrumental in modeling peroxisomal disorders, such as Zellweger spectrum diseases, where EHHADH dysfunction disrupts fatty acid oxidation, leading to metabolic imbalances.
Beyond basic research, recombinant EHHADH aids in drug discovery, particularly for metabolic syndromes, diabetes, or rare genetic disorders linked to β-oxidation defects. Its purified form allows high-throughput screening of enzyme inhibitors or activators. Additionally, it serves as an antigen for antibody development, supporting diagnostic tools for peroxisomal diseases. Recent studies further explore its potential role in cancer metabolism, as altered fatty acid oxidation is observed in tumor progression. Overall, recombinant EHHADH remains a vital tool for unraveling metabolic pathways and advancing targeted therapies.
×
